Advaxis, Inc. (OTCQB:ADXS) (“Advaxis” or the “Company”), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that three abstracts describing research with Advaxis Lm-LLO immunotherapies have been selected for poster presentation at the Society for Immunotherapy of Cancer (SITC) 28th Annual Meeting, November 8-10, 2013 at the Gaylord National Hotel & Convention Center in National Harbor, MD.

The abstract titled “Listeria monocytogenes (Lm)-LLO immunotherapies reduce the immunosuppressive activity of myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironment” has been selected for oral presentation during the session, “Tumor Microenvironment and Innate Cells Recognition" on November 8, 2013 from 9:40 AM to 12:00 PM. Anu Wallecha, Ph.D., Director of Research and Development at Advaxis, will report on the localized effects of Lm-LLO immunotherapies on the tumor microenvironment in preclinical studies using transplantable mouse models.

The abstract titled “ADXS11-001 immunotherapy targeting HPV-E7: Updated survival and safety data from a Phase 2 study in Indian women with recurrent/refractory cervical cancer” has been selected for poster presentation during the Vaccine session. Robert Petit, Ph.D., Chief Scientific Officer of Advaxis, will present final 18-month survival and updated safety data from the ongoing trial.

The abstract titled “Biomarker identification in serum samples from patients with recurrent cervical cancer treated with ADXS11-001 immunotherapy” has been selected for poster presentation during the session “Biomarkers and Immunoscoring”. Poonam Molli, Ph.D., Senior Scientist at Advaxis, will report on the correlation of changes in cytokine and chemokine levels pre- and post-dosing with ADXS11-001 from the Phase 2 study in Indian women with recurrent/refractory cervical cancer.

“The three presentations of Advaxis data at SITC reflect our growing understanding of the unique attributes of the Advaxis platform technology for immunotherapies. Dr. Wallecha’s presentation will highlight the ability of Lm-LLO immunotherapy to counteract immune suppressor cells that enable persistence of the tumor. We will report final 18-month survival and final tumor response data from our 110 patient Phase 2 study in India in women with recurrent cervical cancer. Dr. Molli’s presentation will illustrate the remarkable immune stimulation that occurs in patients after treatment with ADXS11-001. Together, these data paint a picture of an immunotherapy that has a strong positive impact on the immune system while at the same time counteracting immune suppression in the tumor microenvironment that can lead to apparent prolonged survival and objective tumor responses from a single immunotherapeutic agent,” commented Dr. Petit.

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein(s) that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.

ADXS-HPV is currently being evaluated in four clinical trials for human papillomavirus (HPV)-associated cancers: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI U.S. study, Clinical Trials.gov Identifier NCT01266460), head & neck cancer (CRUK study, Clinical Trials.gov Identifier NCT01598792), and anal cancer (BrUOG study, Clinical Trials.gov Identifier NCT01671488). Advaxis has over 15 distinct immunotherapies in various stages of development, developed directly by Advaxis and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the University of Pennsylvania, the Georgia Regent University Cancer Center, the Karolinska Institutet, and others.

For more information please visit: http://www.advaxis.com

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements regarding the ability of ADXS-HPV to lead to apparent prolonged survival and objective tumor responses from a single immunotherapeutic agent. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis' SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2012, which is available at http://www.sec.gov. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.


Contacts

Advaxis, Inc.
Diana Moore, 609-452-9814
Director, Investor Relations & Business Development
dmoore@advaxis.com
or
Jenene Thomas Communications, LLC
Jenene Thomas, 908-938-1475
Investor Relations and Corporate Communications Advisor
thomasjenene@gmail.com